
|Videos|January 11, 2023
Dr. Slovin shares her experience with CAR T-cell therapy in prostate cancer
Author(s)Urology Times staff
Slovin says what’s interesting about the CAR-T platform she’s been exploring is that “we see pretty exquisite sensitivity to the cancer cells.”
Advertisement
Susan F. Slovin, MD, PhD, medical oncologist, associate vice chair, Academic Affairs, Department of Medicine, Memorial Sloan Kettering Cancer Center, discusses her experience with CAR T-cell therapy as an emerging treatment for patients with prostate cancer.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Dosing begins in trial of alpha radioligand therapy for mCRPC
2
Estradiol and ADT: Lessons from Lived Experience
3
Mark Tyson, MD, highlights ADVANCED-2 trial in BCG-naïve NMIBC
4
High PHI scores are linked to increased odds of significant prostate cancer
5


















